Answers are grounded in this paper and cite their sources.
Policy analysis reveals multi-stakeholder funding accelerated MEK inhibitor trials for neurofibromatosis type 1 tumors, highlighting collaborative models for rare disease drug development.
The time from target identification to new drug approval is often measured in decades. This can be even more challenging for rare diseases. Indeed, 95% of rare diseases do not have a specific therapy approved. Coordinated efforts to support research along the drug development pipeline can provide long term and comprehensive support to enable scientific breakthroughs for rare diseases. However, this requires coordination across multiple stakeholders. The present article analyzes the funding efforts of four major federal and philanthropic organizations to accelerate the advancement of MEK inhibitors to human clinical trials for NF1-associated tumors.
No takes yet. Share an insight, caveat, or question.
Rosa et al. (2019) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: